No Signs of Abuse Potential with Eluxadoline in IBS-D

This article originally appeared here.
Data from three randomized trials show no signs of abuse potential for 75, 100 mg eluxadoline
Data from three randomized trials show no signs of abuse potential for 75, 100 mg eluxadoline

HealthDay News — For patients with irritable bowel syndrome with diarrhea (IBS-D), there are no signs of abuse potential for eluxadoline, according to a study published in the July issue of Clinical Gastroenterology and Hepatology.

Reginald V. Fant, PhD, from Pinney Associates in Bethesda, Md., and colleagues examined the abuse potential of eluxadoline in one phase 2 and two phase 3 randomized controlled trials. Enrolled patients met the Rome III criteria for IBS-D and received twice-daily treatment with eluxadoline or placebo for 12, 26, or 52 weeks; with 807 and 1,032 patients receiving one or more doses of 75 or 100mg eluxadoline, respectively, and 975 receiving placebo. 

Related Articles

The researchers found that there was no significant difference between the groups in terms of adverse events potentially related to abuse (2.8, 2.7, and 4.3%, respectively, for those given placebo, eluxadoline 75mg, or eluxadoline 100mg). Anxiety and somnolence were the most common adverse events potentially related to abuse, and they occurred in fewer than 2% of patients in each group. There was no significant difference between the groups in terms of the median overall Subjective Opiate Withdrawal Scale scores (3, 2, and 3, respectively, for those given placebo, eluxadoline 75mg, and eluxadoline 100mg).

"In an analysis of data from Phase 2 and Phase 3 trials of eluxadoline (75 or 100mg) for patients with IBS-D, data revealed no signs of abuse potential for eluxadoline," the authors write.

The study was funded by Furiex Pharmaceuticals, a subsidiary of Allergan, which manufactures eluxadoline.

Abstract
Full Text